Recent News

• 04.23.2025 - Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board
• 04.23.2025 - Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board
• 04.21.2025 - Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East
• 04.21.2025 - Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East
• 04.05.2025 - Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease
• 04.05.2025 - Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease
• 03.31.2025 - Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference
• 03.31.2025 - Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference
• 02.24.2025 - Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference
• 02.24.2025 - Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

Recent Filings

• 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]